The $949M Omnicare Verdict Just Closed. The $290M Behnke Ruling Is Why Tort Risk Now Outweighs FTC Risk at CVS Health

On April 29, 2025, a federal jury in Manhattan found CVS Health's Omnicare unit liable under the False Claims Act for 3,342,032 false claims filed between 2010 and 2018 — drugs dispensed to long-term care residents without valid physician authorization. The jury pegged federal losses at $135.6 million. Two months later, Judge Colleen McMahon trebled the damages to $406.8 million and imposed a $542 million civil penalty, bringing the total judgment to $948.8 million. The court also held CVS jointly liable for $164.8 million of those penalties after jurors found it failed to stop30% of the false claims once it acquired Omnicare in 2015.

Two months after judgment, on Sept. 22, 2025, Omnicare and 109 affiliated entities filed for Chapter 11 protection in the Northern District of Texas, citing liabilities of up to $10 billion against assets of roughly $500 million. CVS deconsolidated the unit the same day, booking a $483 million gain on deconsolidation. The Department of Justice filed what it called the \"single largest claim\" against the bankruptcy estate in early 2026, and on July 8, 2026, CVS and Omnicare settled the matter for at least $440 million — $130 million due from CVS within two weeks and a $310 million tail due by the end of March 2028.

Stripping Omnicare from CVS is more than a balance-sheet cleanup — it removes a long-term-care distribution arm that had been loss-making since 2015. The May2026 sale to GenieRx Holdings — a joint venture of Milrose Capital and Integro Asset Management — values the operating business at $250 million, with CVS separately obligated to the $440 million DOJ settlement. Inside CVS's consolidated results, the wind-down drops long-term-care prescription volume entirely from Q4 2025 forward, which is one of the reasons Q2 2026 revenue grew 7.3% year-over-year despite the unit's absence.

Q2 2026 was the cleanest print post-Omnicare. Total revenue hit $106.1 billion, GAAP diluted EPS came in at $2.31, and Adjusted EPS reached $2.58 — both well above consensus. CVS raised full-year 2026 Adjusted EPS guidance to $7.90–$8.10 (from $7.30–$7.50) and operating cash flow guidance to at least $11.5 billion. The Health Services segment, which houses CVS Caremark, posted $51.8 billion of revenue (+11.5% YoY), and Health Care Benefits (Aetna) added over $37 billion. S&P revised CVS's outlook to Stable from Negative on May 21, 2026 — a meaningful credit read-through given the company's $59.5 billion of long-term debt and $65.0 billion of net debt at quarter-end.

On June 25, 2025, Chief U.S. District Judge Mitchell Goldberg of the Eastern District of Pennsylvania found CVS Caremark liable for $95 million in actual damages for inflating Medicare Part D drug costs through \"spread pricing\" — the gap between what a PBM charges a plan sponsor and what it reimburses the dispensing pharmacy. The relator was Sarah Behnke, a former Aetna head actuary who moved into a Caremark role and noticed the discrepancy internally. Two months later, the court trebled the damages to $285 million and added $4.87 million in civil penalties on 513 false reports, for a final judgment of $289,873,500. CVS Caremark has appealed to the Third Circuit.

The Behnke case is structurally different from Omnicare. Omnicare was a dispensing fraud — falsified claims tied to a single unit's compliance failure. Behnke attacks the PBM spread-pricing model itself: the practice of charging Aetna's Medicare Part D plan more for the same drug than Caremark charged non-Aetna clients, with the spread retained by the PBM. That mechanism is exactly the same one the FTC has been pursuing against Caremark, Cigna's Express Scripts, and UnitedHealth Group's OptumRx in a 2024 administrative action that yielded the February 2026 Express Scripts settlement and the July 14, 2026 Caremark settlement.

For Cigna and UnitedHealth Group, the read-through is direct. Both PBMs use spread pricing; both faced the same 2024 FTC complaint; both settled on the same structural template Express Scripts accepted in February 2026. The open question — now squarely on the table after Behnke — is whether relators can survive an FCA motion to dismiss and reach trial on the same theory Behnke proved. The $289.9M Behnke judgment establishes that the model survives constitutional challenge on damages (Judge Goldberg rejected Caremark's Excessive Fines and Due Process arguments in the Aug. 19, 2025 ruling), which makes it actionable as a template by relators inside any of the three PBMs.

Omnicare sat at the intersection of three large U.S. drug channels. As a long-term-care pharmacy, it sourced from the big-three drug wholesalers — McKesson and Cardinal Health are the two publicly traded players most exposed to LTC distribution — and it billed government payers through PBM relationships anchored in CVS Caremark. Stripping it out via a $250 million GenieRx sale changes the routing, not the demand: skilled nursing and assisted-living facilities still need closed-door pharmacy services, and the underlying drug volumes still flow through the wholesaler tier.

The combined tort plus regulatory pressure is now large enough that CVS's bull case has to price it in. The two verdicts together (~$1.24 billion before appeals and trebling multipliers on parallel cases) plus the FTC-mandated pass-through of rebates and the wind-down of Omnicare's vertical integration story leave the Caremark-plus-Aetna-plus-retail thesis intact on revenue ($415B+ TTM run-rate) but reduced on optionality. Forward earnings power is the bet: CVS is guiding to $7.90–$8.10 of Adjusted EPS in 2026, the stock trades at a forward P/E of 10.7x, and S&P's outlook revision to Stable effectively underwrites that recovery.

Short-term (days–quarters), three dates matter. The Omnicare wind-down plan is scheduled to go effective in October 2026, transferring the operating business to GenieRx and terminating CVS's residual indemnity. The DOJ settlement hearing is set for Aug. 12, 2026 — already past as of this writing — but the second $310 million installment from CVS is not due until March 31, 2028, so the cash drag is back-loaded. And Behnke's appellate track at the Third Circuit will produce the next concrete read on whether spread-pricing verdicts survive appeal; any affirmance raises the read-through probability for similar relator cases against Cigna and UnitedHealth Group.

Long-term (1–3 years), the structural shift is already in motion. The Caremark settlement forces $4.5 billion in point-of-sale rebate pass-through over ten years, the FTC has signaled industry-wide application, and January 1, 2026 brought new state and federal rules banning PBM spread pricing in contracts executed or amended after that date. That shrinks the addressable spread pool — historically a double-digit-billion-dollar line at the big three — and pushes the PBM business toward transparent administrative fees. For CVS, the question is whether Caremark can grow volume and Aetna medical-cost improvements (Q2 2026's MLR dropped ~270 bps YoY) fast enough to offset; for Cigna, the Evernorth PBM book faces the same pressure; for UnitedHealth Group, OptumRx volume and rebates are the swing factor.